Clinical Trials · NCT00516074
A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 54
- Start date
- Sep 2007
- Locations
- 6 sites, Canada, Netherlands
- Primary endpoint
- Change in Mean 24-hour Heart Rate From Baseline to Endpoint